藥物洗脫支架（DES）的誕生和不斷優(yōu)化已經(jīng)大大提高了經(jīng)皮冠狀動(dòng)脈介入治療（PCI）的安全性和有效性,，但隨著病例復(fù)雜性的增加和DES的超適應(yīng)證應(yīng)用,，術(shù)后再狹窄率正逐年上升。因此,，當(dāng)前DES時(shí)代下,，支架內(nèi)再狹窄（ISR）仍是臨床上亟待解決的一大難題。本文將主要就DES置入后ISR發(fā)生發(fā)展的病理機(jī)制,、組織病理學(xué)及治療策略的最新研究成果及進(jìn)展進(jìn)行綜述,。

The advent and subsequent iterations of drug-eluting stent（DES） technologies have significantly improved the safety and efficacy of percutaneous coronary interventions（PCI）.However，with the increasing complexity of cases and off-label use of DES,，the restenosis rates with DES are rising year by year. Therefore,，in-stent restenosis（ISR） in the current DES era is still a major clinical challenge that needs to be addressed. This paper mainly reviews the latest research findings and progress on the pathological mechanisms，histopathology and treatment strategies of ISR after DES implantation.

掃碼下載全文